Braidwell LP Sells 304,802 Shares of Dianthus Therapeutics, Inc. $DNTH

Braidwell LP decreased its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 33.9% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 594,562 shares of the company’s stock after selling 304,802 shares during the period. Dianthus Therapeutics comprises approximately 2.2% of Braidwell LP’s investment portfolio, making the stock its 12th biggest holding. Braidwell LP owned approximately 1.09% of Dianthus Therapeutics worth $57,958,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in DNTH. Vanguard Group Inc. lifted its holdings in Dianthus Therapeutics by 24.7% during the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after purchasing an additional 406,254 shares during the last quarter. UBS Group AG lifted its stake in shares of Dianthus Therapeutics by 342.6% during the 4th quarter. UBS Group AG now owns 606,620 shares of the company’s stock worth $24,999,000 after buying an additional 469,547 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Dianthus Therapeutics by 1,275.3% during the 4th quarter. BNP Paribas Financial Markets now owns 475,749 shares of the company’s stock worth $19,606,000 after buying an additional 441,156 shares during the last quarter. SummitTX Capital L.P. lifted its stake in shares of Dianthus Therapeutics by 13.8% during the 1st quarter. SummitTX Capital L.P. now owns 100,044 shares of the company’s stock worth $8,396,000 after buying an additional 12,118 shares during the last quarter. Finally, California State Teachers Retirement System boosted its holdings in shares of Dianthus Therapeutics by 155.5% during the 1st quarter. California State Teachers Retirement System now owns 40,584 shares of the company’s stock worth $3,406,000 after buying an additional 24,697 shares during the period. 47.53% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have issued reports on DNTH. Wedbush raised their price objective on shares of Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Truist Financial upped their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Finally, Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $124.27.

Dianthus Therapeutics Stock Down 0.4%

Shares of Dianthus Therapeutics stock opened at $106.24 on Thursday. The stock has a market capitalization of $5.81 billion, a price-to-earnings ratio of -25.60 and a beta of 1.24. Dianthus Therapeutics, Inc. has a twelve month low of $23.66 and a twelve month high of $117.88. The company has a 50-day simple moving average of $104.65 and a two-hundred day simple moving average of $88.52.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The business had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. On average, sell-side analysts anticipate that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current fiscal year.

Insider Buying and Selling at Dianthus Therapeutics

In other Dianthus Therapeutics news, Director Simon Read sold 2,778 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $117.55, for a total transaction of $326,553.90. Following the transaction, the director owned 2,778 shares in the company, valued at $326,553.90. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Anne Mcgeorge sold 7,750 shares of Dianthus Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $109.01, for a total value of $844,827.50. Following the completion of the transaction, the director directly owned 1,250 shares of the company’s stock, valued at $136,262.50. This represents a 86.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 260,554 shares of company stock valued at $27,211,775 over the last ninety days. 3.02% of the stock is owned by corporate insiders.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.